Cargando…

Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort

The Framingham Risk Score to predict 30-year risk (FRS30y) of cardiovascular disease (CVD) constitutes an important tool for long-term risk prediction. However, due to its complex statistical properties and the paucity of large population-based cohorts with appropriate data, validation of the FRS30y...

Descripción completa

Detalles Bibliográficos
Autores principales: Rospleszcz, Susanne, Starnecker, Fabian, Linkohr, Birgit, von Scheidt, Moritz, Gieger, Christian, Schunkert, Heribert, Peters, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025787/
https://www.ncbi.nlm.nih.gov/pubmed/35454012
http://dx.doi.org/10.3390/diagnostics12040965
_version_ 1784690960496590848
author Rospleszcz, Susanne
Starnecker, Fabian
Linkohr, Birgit
von Scheidt, Moritz
Gieger, Christian
Schunkert, Heribert
Peters, Annette
author_facet Rospleszcz, Susanne
Starnecker, Fabian
Linkohr, Birgit
von Scheidt, Moritz
Gieger, Christian
Schunkert, Heribert
Peters, Annette
author_sort Rospleszcz, Susanne
collection PubMed
description The Framingham Risk Score to predict 30-year risk (FRS30y) of cardiovascular disease (CVD) constitutes an important tool for long-term risk prediction. However, due to its complex statistical properties and the paucity of large population-based cohorts with appropriate data, validation of the FRS30y is lacking. A population-based cohort from Southern Germany (N = 3110, 1516 (48.7%) women) was followed up for a median time of 29.5 [18.7, 31.2] years. Discrimination and calibration were assessed for the original, recalibrated and refitted FRS30y version. During follow up, 620 incident CVD events (214 in women) occurred. The FRS30y showed adequate discrimination (original and recalibrated version: Area under the curve (AUC): 78.4 for women and 74.9 for men) but overestimated actual CVD risk (original version: discordance 45.4% for women and 37.3% for men, recalibrated version: 37.6% and 28.6%, respectively). Refitting showed substantial improvement in neither discrimination nor calibration. The performance of FRS30y is adequate for long-term CVD risk prediction and could serve as an important tool in risk communication, especially for younger audiences.
format Online
Article
Text
id pubmed-9025787
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90257872022-04-23 Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort Rospleszcz, Susanne Starnecker, Fabian Linkohr, Birgit von Scheidt, Moritz Gieger, Christian Schunkert, Heribert Peters, Annette Diagnostics (Basel) Article The Framingham Risk Score to predict 30-year risk (FRS30y) of cardiovascular disease (CVD) constitutes an important tool for long-term risk prediction. However, due to its complex statistical properties and the paucity of large population-based cohorts with appropriate data, validation of the FRS30y is lacking. A population-based cohort from Southern Germany (N = 3110, 1516 (48.7%) women) was followed up for a median time of 29.5 [18.7, 31.2] years. Discrimination and calibration were assessed for the original, recalibrated and refitted FRS30y version. During follow up, 620 incident CVD events (214 in women) occurred. The FRS30y showed adequate discrimination (original and recalibrated version: Area under the curve (AUC): 78.4 for women and 74.9 for men) but overestimated actual CVD risk (original version: discordance 45.4% for women and 37.3% for men, recalibrated version: 37.6% and 28.6%, respectively). Refitting showed substantial improvement in neither discrimination nor calibration. The performance of FRS30y is adequate for long-term CVD risk prediction and could serve as an important tool in risk communication, especially for younger audiences. MDPI 2022-04-12 /pmc/articles/PMC9025787/ /pubmed/35454012 http://dx.doi.org/10.3390/diagnostics12040965 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rospleszcz, Susanne
Starnecker, Fabian
Linkohr, Birgit
von Scheidt, Moritz
Gieger, Christian
Schunkert, Heribert
Peters, Annette
Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort
title Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort
title_full Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort
title_fullStr Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort
title_full_unstemmed Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort
title_short Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort
title_sort validation of the 30-year framingham risk score in a german population-based cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025787/
https://www.ncbi.nlm.nih.gov/pubmed/35454012
http://dx.doi.org/10.3390/diagnostics12040965
work_keys_str_mv AT rospleszczsusanne validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort
AT starneckerfabian validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort
AT linkohrbirgit validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort
AT vonscheidtmoritz validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort
AT giegerchristian validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort
AT schunkertheribert validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort
AT petersannette validationofthe30yearframinghamriskscoreinagermanpopulationbasedcohort